JP2018535989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535989A5 JP2018535989A5 JP2018527797A JP2018527797A JP2018535989A5 JP 2018535989 A5 JP2018535989 A5 JP 2018535989A5 JP 2018527797 A JP2018527797 A JP 2018527797A JP 2018527797 A JP2018527797 A JP 2018527797A JP 2018535989 A5 JP2018535989 A5 JP 2018535989A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- acid
- cytarabine
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 26
- 229960000684 cytarabine Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000015879 Cerebellar disease Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 230000005983 bone marrow dysfunction Effects 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 235000010338 boric acid Nutrition 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 229940013688 formic acid Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 229940032330 sulfuric acid Drugs 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 208000016595 therapy related acute myeloid leukemia and myelodysplastic syndrome Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- PMPGFXNTGCSYLL-WJARAWPISA-N NC(CC(NC(C=CN1[C@@H](C23OC2)O[C@H](CO)C3O)=NC1=O)=O)C(O)=O Chemical compound NC(CC(NC(C=CN1[C@@H](C23OC2)O[C@H](CO)C3O)=NC1=O)=O)C(O)=O PMPGFXNTGCSYLL-WJARAWPISA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262428P | 2015-12-03 | 2015-12-03 | |
| US62/262,428 | 2015-12-03 | ||
| PCT/IL2016/050077 WO2017093993A1 (en) | 2015-12-03 | 2016-01-25 | Cytarabine conjugates for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020122708A Division JP2020183419A (ja) | 2015-12-03 | 2020-07-17 | 癌治療のためのシタラビンコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535989A JP2018535989A (ja) | 2018-12-06 |
| JP2018535989A5 true JP2018535989A5 (cg-RX-API-DMAC7.html) | 2019-03-07 |
| JP7149183B2 JP7149183B2 (ja) | 2022-10-06 |
Family
ID=58796462
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527797A Active JP7149183B2 (ja) | 2015-12-03 | 2016-01-25 | 癌治療のためのシタラビンコンジュゲート |
| JP2020122708A Pending JP2020183419A (ja) | 2015-12-03 | 2020-07-17 | 癌治療のためのシタラビンコンジュゲート |
| JP2022077787A Active JP7417658B2 (ja) | 2015-12-03 | 2022-05-10 | 癌治療のためのシタラビンコンジュゲート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020122708A Pending JP2020183419A (ja) | 2015-12-03 | 2020-07-17 | 癌治療のためのシタラビンコンジュゲート |
| JP2022077787A Active JP7417658B2 (ja) | 2015-12-03 | 2022-05-10 | 癌治療のためのシタラビンコンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11058701B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3383407B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7149183B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108289905A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016362830B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018011177A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007058C (cg-RX-API-DMAC7.html) |
| IL (2) | IL259631B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2708672C1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017093993A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3383883A4 (en) | 2015-12-03 | 2019-07-24 | BioSight Ltd. | SALTS OF CONJUGATES TO CANCER THERAPY |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| CN110590862A (zh) * | 2019-11-01 | 2019-12-20 | 南京师范大学 | 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用 |
| CN115052607A (zh) * | 2020-02-04 | 2022-09-13 | 拜欧赛特有限公司 | 天冬阿糖胞苷药物组合物和其用途 |
| JP2023522420A (ja) * | 2020-04-23 | 2023-05-30 | バイオサイト リミテッド | 血液がんの治療のための方法及びレジメン |
| IL301526A (en) * | 2020-09-21 | 2023-05-01 | Biosight Ltd | Crystalline form of aspacytarabine |
| CN112409431B (zh) * | 2020-12-07 | 2023-04-21 | 武汉伯瑞恒医药科技有限公司 | 阿糖胞苷结构类似物及其制备方法和用途 |
| CN118434752A (zh) * | 2021-11-21 | 2024-08-02 | 拜欧赛特有限公司 | 用于治疗癌症的基于阿糖胞苷-氨基酸的前药 |
| WO2023175622A1 (en) * | 2022-03-17 | 2023-09-21 | Biosight Ltd. | Crystalline forms of aspacytarabine |
| WO2023228177A1 (en) * | 2022-05-22 | 2023-11-30 | Biosight Ltd. | Compositions comprising aspacytarabine and additional compounds, and use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2949451A (en) | 1959-04-21 | 1960-08-16 | Hoffmann La Roche | Preparation of thymidine and deoxyfluorouridine, and intermediates therefor |
| US3041335A (en) | 1959-04-21 | 1962-06-26 | Hoffmann La Roche | Mercury salts of nitrogen heterocyclics and preparation thereof |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4296105A (en) | 1978-08-03 | 1981-10-20 | Institut International De Pathologie Cellulaire Et Moleculaire | Derivatives of doxorubicine, their preparation and use |
| US4348522A (en) | 1980-01-23 | 1982-09-07 | Starks Associates, Inc. | N-(phosphonacetyl)-L-aspartic acid salts with piperazine, cyclohexylamine and calcium |
| EP0329184A3 (en) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
| US6344213B1 (en) | 1996-03-29 | 2002-02-05 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| RU2085557C1 (ru) | 1991-09-30 | 1997-07-27 | Санкио Компани Лимитед | Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения |
| US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| JPH09510696A (ja) * | 1994-01-11 | 1997-10-28 | ターゲテック インコーポレイテッド | 肝細胞を標的とする薬物結合体 |
| CA2203622C (en) | 1994-08-19 | 2011-11-01 | Andre Trouet | Compounds, pharmaceutical composition and diagnostic device comprising them and their use |
| JPH0859688A (ja) | 1994-08-25 | 1996-03-05 | Mitsui Toatsu Chem Inc | ５’−チオノエステル置換トリフルオロチミジン誘導体およびそれを有効成分とする制癌剤 |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| ATE460180T1 (de) | 1998-12-11 | 2010-03-15 | Coulter Pharm Inc | Prodrugs und verfahren zu deren herstellung |
| EP1556393B1 (en) | 2002-10-31 | 2013-12-25 | Metabasis Therapeutics, Inc. | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
| WO2005072061A2 (en) | 2004-02-02 | 2005-08-11 | Biosight Ltd. | Conjugates for cancer therapy and diagnosis |
| WO2008072963A1 (en) | 2006-12-13 | 2008-06-19 | Givaudan Nederland Services B.V. | Flavour modulating derivative of a carboxylic acid and a purine, pyrimidine, nucleoside or nucleotide |
| CN101812105A (zh) | 2009-02-25 | 2010-08-25 | 沈阳药科大学 | 阿糖胞苷5’-o-氨基酸酯和其盐类及其制备方法 |
| JP5873656B2 (ja) * | 2011-06-13 | 2016-03-01 | 株式会社Ihi | 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤 |
| KR20140079831A (ko) | 2011-10-18 | 2014-06-27 | 아지노모토 가부시키가이샤 | 췌장암 및／또는 담도암 치료약 |
| US20150328245A1 (en) | 2012-12-18 | 2015-11-19 | Godavari Biorefineries Limited | Agents for Eliminating Tumour-Initiating Cells |
| WO2015178265A1 (ja) | 2014-05-23 | 2015-11-26 | 日本化薬株式会社 | 新規なグルタミン酸誘導体およびその用途 |
-
2016
- 2016-01-25 CN CN201680070972.5A patent/CN108289905A/zh active Pending
- 2016-01-25 WO PCT/IL2016/050077 patent/WO2017093993A1/en not_active Ceased
- 2016-01-25 RU RU2018119319A patent/RU2708672C1/ru active
- 2016-01-25 US US15/780,732 patent/US11058701B2/en not_active Expired - Fee Related
- 2016-01-25 CA CA3007058A patent/CA3007058C/en active Active
- 2016-01-25 BR BR112018011177A patent/BR112018011177A2/pt not_active Application Discontinuation
- 2016-01-25 JP JP2018527797A patent/JP7149183B2/ja active Active
- 2016-01-25 EP EP16870114.2A patent/EP3383407B1/en active Active
- 2016-01-25 AU AU2016362830A patent/AU2016362830B2/en not_active Ceased
-
2018
- 2018-05-27 IL IL259631A patent/IL259631B/en unknown
-
2020
- 2020-07-17 JP JP2020122708A patent/JP2020183419A/ja active Pending
-
2021
- 2021-10-27 IL IL287644A patent/IL287644A/en unknown
-
2022
- 2022-05-10 JP JP2022077787A patent/JP7417658B2/ja active Active
- 2022-06-22 AU AU2022204373A patent/AU2022204373B2/en not_active Ceased